Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
about
Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infectionApproved Antiviral Drugs over the Past 50 YearsHIV and kidney diseases: 35 years of history and consequencesNew Antiretroviral Treatment for HIVEnding the HIV/AIDS epidemic in low- and middle-income countries by 2030: is it possible?A Review of Management of Inflammation in the HIV PopulationProfile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to dateKidney Disease and HIV Infection.Cardiovascular Complications of HIV Infection.Bone health in HIV and hepatitis B or C infectionsHIV infection and bone disease.What's new for antiretroviral treatment in women with HIVProjected Uptake of New Antiretroviral (ARV) Medicines in Adults in Low- and Middle-Income Countries: A Forecast Analysis 2015-2025.Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed AdultsKey toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen.Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells.Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells.In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.Real-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens.Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations.The preexposure prophylaxis revolution: from clinical trials to routine practice: implementation view from the USA.Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.Is Abnormal Urine Protein/Osmolality Ratio Associated with Abnormal Renal Function in Patients Receiving Tenofovir Disoproxil Fumarate?Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV.Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 StudyTenofovir and bone health.Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.Adverse bone health among children and adolescents growing up with HIV.Viral hepatitis: Indian scenario.The effect of Tenofovir on renal function among Ugandan adults on long-term antiretroviral therapy: a cross-sectional enrolment analysis.Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA PanelThe Anticipated Clinical and Economic Effects of 90-90-90 in South Africa.Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir-DF-associated renal tubulopathy.The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis.Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected AdultsBrief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected AdultsEquivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide.Pharmaceutical characterization of novel tenofovir liposomal formulations for enhanced oral drug delivery: in vitro pharmaceutics and Caco-2 permeability investigationsReview of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection.
P2860
Q26750406-5A88AB80-B67E-47CB-B357-068BC58F977AQ27755387-412065BD-E21E-421E-9A8B-ADD501437CCBQ28069641-3F7FDB7B-33DD-4B73-B4EA-5301C3C01F2EQ28069829-41374875-255A-444E-BBBF-F5E1EA6BEF4EQ28073723-42342781-C927-4E7F-8495-590980E6B6FDQ28078962-DD659D28-3C89-4FF0-BF5E-63F006542542Q28079025-D1E7E212-AEBB-4923-B0E4-47821DA84004Q30234837-2728F6B2-CF91-49D9-A4BD-80D27DCDB698Q30235920-DF6EC99E-2306-4F2A-936C-6CEE82E0E5A3Q30238946-7925EE3F-399F-4335-B986-1D4F09256FA3Q30249771-EA5A0E3F-BD6D-440D-B520-9635AA5603D8Q30391322-1CCBF067-864B-4135-92AF-5BCA13592293Q30394059-E756C7C4-2919-4A06-B046-602B3B943829Q33669829-57927404-63CC-4B81-8329-AC1F84D38711Q34536677-EDE74C8A-4EA2-4099-BC35-BF0A6DB05FCDQ35833324-F3A99B8E-8D29-4EDA-8196-DB98EB010B89Q36075888-E0E6D81E-AA5C-487A-A9AE-0A653667C10DQ36075908-1510C84D-6E68-430B-BAFD-23E4189E0F98Q36219963-AEF91D32-D9D1-4988-8FA8-BE1F9FFDA6F9Q36275141-7388DCF0-FDE9-4FCC-9BBC-1E56F9E05022Q36348296-816B6834-C3AD-4004-A688-0F0B1C500581Q36426953-67B9CD83-DE1E-45CE-9137-2A24EBE74B5CQ36576316-E3423456-4B06-4E8C-9A39-2B00BD969A2CQ36663586-5AB658AC-6024-4DAF-9ADD-62C849CF5DD9Q36721012-526286EB-97A7-42E3-8275-1E8D25B68EFFQ36833961-A6D99B3D-9082-49F9-9159-8DDB5F6BA7FBQ36988748-5827F552-28A0-4788-9A6F-CDC47938E8CDQ37098360-BD8848D5-7C69-4F07-A76B-E3E9A5F8AFA5Q37171340-3414FDD1-479F-48E1-9810-B6BC24855C68Q37221374-BB34CF70-3D40-4F58-9FE3-CC27EE575DA7Q37234729-582D0D08-A723-4D02-A31A-A6AD9A1C2185Q37235371-B9318C1B-8930-4B82-AAB3-D92C01AD47FEQ37242504-EFC4ACF8-DB4D-44F1-8248-2919FA80888DQ37354871-2BCB509F-F94C-4D81-9013-B71DBCD57190Q37519831-6D223EB6-25C2-4F9A-B0E9-C8A9683722A2Q37582471-349F8893-E895-4000-8136-0522085A0C37Q37582474-ADD05F38-3244-472D-8E5E-CC7031B9A99DQ37604553-C343B402-5CE7-4BB1-AF79-EB9483054651Q37669191-8A6F49A7-D994-482B-9244-E02CAF555A6AQ38570500-0E122582-906D-4CC9-B671-A51D84C83D90
P2860
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Tenofovir alafenamide versus t ...... ase 3, non-inferiority trials.
@en
type
label
Tenofovir alafenamide versus t ...... ase 3, non-inferiority trials.
@en
prefLabel
Tenofovir alafenamide versus t ...... ase 3, non-inferiority trials.
@en
P2093
P1433
P1476
Tenofovir alafenamide versus t ...... ase 3, non-inferiority trials.
@en
P2093
Andrew K Cheng
Andrew Plummer
Anton Pozniak
Benoit Trottier
Christian Callebaut
Daniel Podzamczer
David Wohl
Edwin DeJesus
Ellen Koenig
Frank Post
P304
P356
10.1016/S0140-6736(15)60616-X
P407
P577
2015-04-15T00:00:00Z